temozolomide and Anaplastic Oligodendroglioma studies

Research Excerpts

Excerpt	Relevance	Reference
"We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma."	9.20	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. ( Brachman, DG; Giannini, C; Hu, C; Jenkins, RB; Laack, NN; Macdonald, DR; Mehta, MP; Peereboom, DM; Shrieve, DC; Souhami, L; Suh, JH; Vogelbaum, MA, 2015)
"The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)."	9.14	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009)
"A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)."	9.13	CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008)
"To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy."	9.12	Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006)
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."	9.11	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
" A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma."	9.09	Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001)
"We report a case of anaplastic oligodendroglioma metastatic to bone with a dramatic and durable response to temozolomide therapy."	8.82	Bony metastases of anaplastic oligodendroglioma respond to temozolomide. ( Bilbao, JM; Morrison, T; Perry, JR; Yang, G, 2004)
"To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)."	8.02	Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021)
"This retrospective analysis investigated outcomes in patients with anaplastic oligodendroglioma 1p19q codeleted compared two different protocols (radiotherapy plus temozolomide or PCV)."	7.88	Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018)
"The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control."	7.80	Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S, 2014)
" We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)."	7.79	IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013)
"We conducted a retrospective observational study that included patients with recurrent malignant glioma who where treated with temozolomide."	7.72	Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003)
"In this IRB-approved retrospective study, we analyzed the efficacy of temozolomide on World Health Organization Grade II and III oligodendrogliomas, as well as mixed oligoastrocytomas, to determine if a correlation exists between the tumors' 1p status and control of growth by this new oral agent."	7.72	Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. ( Barnett, G; Chahlavi, A; Elson, P; Kanner, A; Peereboom, D; Staugaitis, SM, 2003)
"The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days."	7.71	Temozolomide chemotherapy in recurrent oligodendroglioma. ( Brandes, AA; Carpentier, AF; Eskens, FA; Keime-Guibert, F; Kros, JM; Taphoorn, MJ; van den Bent, MJ, 2001)
"Temozolomide was given 150 mg/m(2) days 1-7 and 15-21, every 28 days for 8 cycles."	6.80	Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H, 2015)
"The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q."	6.74	Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. ( Anderson, J; Avedissian, R; Croteau, D; Doyle, T; Gutierrez, J; Hasselbach, L; Margolis, J; Mikkelsen, T; Paleologos, N; Schultz, L, 2009)
"Temozolomide was in general well tolerated; the most frequent side-effects were hematological."	6.71	Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003)
"Adults (>18) with newly diagnosed 1p/19q World Health Organization (WHO) grade III oligodendroglioma were randomized to radiotherapy (RT; 5940 centigray ) alone (arm A); RT with concomitant and adjuvant temozolomide (TMZ) (arm B); or TMZ alone (arm C)."	5.41	CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. ( Aldape, KD; Anderson, SK; Ballman, KV; Brown, PD; Cairncross, JG; Cerhan, JH; Dhermain, F; Dixon, JG; Flynn, PJ; Galanis, E; Giannini, C; Grossman, SA; Jaeckle, KA; Jenkins, RB; Klein, M; Nordstrom, DG; Raizer, JJ; Schiff, D; van den Bent, M; Vogelbaum, MA; Wefel, JS; Weller, M; Wick, W, 2021)
"Histology revealed an anaplastic oligodendroglioma."	5.37	Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide. ( Lou, X; Qiao, G; Wang, F, 2011)
"Gliomas account for more than 50% of all primary brain tumors."	5.36	Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. ( Bontempi, G; Bruyère, C; Decaestecker, C; Dubois, J; Haibe-Kains, B; Kiss, R; Lamoral-Theys, D; Le Calvé, B; Le Mercier, M; Lefranc, F; Rynkowski, MA, 2010)
"The diagnosis of an anaplastic oligodendroglioma (WHO grade 3) was made on pathological examination."	5.35	Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. ( Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI, 2009)
"We report on the long-term results of a phase II study of pre-irradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma."	5.20	Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. ( Brachman, DG; Giannini, C; Hu, C; Jenkins, RB; Laack, NN; Macdonald, DR; Mehta, MP; Peereboom, DM; Shrieve, DC; Souhami, L; Suh, JH; Vogelbaum, MA, 2015)
" Forty newly diagnosed patients (11 anaplastic oligodendrogliomas [OD] and 29 anaplastic oligoastrocytomas [OA]) were enrolled into this multicenter, open-label, single-arm Phase II trial of first-line temozolomide (200 mg/m(2) on days 1-5 every 4 weeks for 6 cycles)."	5.14	A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors. ( Algar, E; Benson, A; Cher, L; Dowling, A; Gan, HK; Kalnins, R; Rosenthal, MA; Wong, N; Woods, AM, 2010)
"The primary objectives of this phase II study were to evaluate the use of preirradiation temozolomide followed by concurrent temozolomide and radiotherapy (RT) in patients with newly diagnosed anaplastic oligodendroglioma (AO) and mixed anaplastic oligoastrocytoma (MOA)."	5.14	Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. ( Berkey, B; Biggs, C; Blumenthal, DT; Brown, P; Giannini, C; Herman, J; Jenkins, R; Macdonald, D; Mehta, M; Peereboom, D; Schultz, C; Suh, JH; Vogelbaum, MA, 2009)
"Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year."	5.14	Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. ( Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA, 2010)
"A Phase II study of CPT-11 in adults with recurrent, temozolomide (TMZ)-refractory, 1p19q co-deleted, anaplastic oligodendroglioma (AO) with a primary objective of determining 6-month progression free survival (PFS)."	5.13	CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. ( Chamberlain, MC; Glantz, MJ, 2008)
"To date, no data are available on the relationship between 1p/19q deletions and the response to temozolomide (TMZ) in primary anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) recurrent after surgery and standard radiotherapy."	5.12	Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. ( Bertorelle, R; Blatt, V; Bonaldi, L; Brandes, AA; Cavallo, G; Ermani, M; Franceschi, E; Gardiman, M; Ghimenton, C; Iuzzolino, P; Pession, A; Reni, M; Tosoni, A, 2006)
"The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma."	5.11	Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. ( Allgeier, A; Brandes, AA; Enting, RH; Frenay, M; Kros, JM; Menten, J; Stege, EB; Taphoorn, MJ; Tosoni, A; Triebels, VH; van den Bent, MJ; van Heuvel, I, 2004)
" A novel second-generation alkylating agent, temozolomide, has recently demonstrated efficacy and safety in patients with recurrent glioblastoma multiforme and anaplastic astrocytoma."	5.09	Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. ( Barrie, M; Braguer, D; Chinot, OL; Dufour, H; Figarella-Branger, D; Grisoli, F; Honore, S; Martin, PM; Muracciole, X, 2001)
"The association of radiotherapy and procarbazine, lomustine (CCNU), vincristine chemotherapy in low-grade oligodendrogliomas is definitely superior over radiotherapy alone, and yields median progression-free survival and overall survival values exceeding by far 10 years."	5.05	Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? ( Rudà, R; Soffietti, R; Touat, M, 2020)
"Anaplastic oligodendrogliomas (AOs) are rare brain tumors responsive to chemotherapy with procarbazine, lomustine (CCNU) and vincristine (PCV), especially when harboring 1p19q codeletion."	4.91	Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? ( Lassman, AB, 2015)
" The place of chemotherapy is growing not only for anaplastic oligodendrogliomas, more chemosensitive (particularly when they harbor 1p19q codeletions), but also for glioblastomas patients, which have been shown to benefit from radiotherapy plus concomitant and adjuvant temozolomide."	4.83	[Pattern of care of high-grade gliomas]. ( Laigle-Donadey, F; Sanson, M, 2006)
"We report a case of anaplastic oligodendroglioma metastatic to bone with a dramatic and durable response to temozolomide therapy."	4.82	Bony metastases of anaplastic oligodendroglioma respond to temozolomide. ( Bilbao, JM; Morrison, T; Perry, JR; Yang, G, 2004)
" Approximately two thirds of patients with the more aggressive form (anaplastic oligodendroglioma) have shown substantial response to first-line procarbazine/lomustine/vincristine (PCV) therapy."	4.81	Chemotherapy for the treatment of oligodendroglial tumors. ( Chinot, O, 2001)
"We report a case of oligodendroglioma that had consistent histopathological features as well as a distinct change in 1p/19q status in the second recurrence, after temozolomide chemotherapy and radiotherapy."	4.12	Recurrent oligodendroglioma with changed 1p/19q status. ( Barresi, V; Calicchia, M; Ghimenton, C; Mafficini, A; Musumeci, A; Piredda, ML; Scarpa, A, 2022)
"To report clinical outcomes of temozolomide (TMZ)-based radio-chemotherapy and adjuvant chemotherapy in patients with aggressive/high-risk low-grade glioma (LGG)."	4.02	Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. ( Anand, S; Chatterjee, A; Epari, S; Goda, JS; Gupta, T; Jalali, R; Krishnatry, R; Moiyadi, A; Panda, P; Patil, V, 2021)
"Patients (n = 142) with molecularly defined oligodendroglioma (WHO 2016) were assigned to four cohorts: W&S, wait-and-scan after stereotactic biopsy (n = 59); RES, surgical resection only (n = 27); TMZ, temozolomide after biopsy (n = 26) or PCV (n = 30) after biopsy."	4.02	PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. ( Egensperger, R; Karschnia, P; Katzendobler, S; Lietke, S; Suchorska, B; Thon, N; Tonn, JC; Weller, J; Weller, M, 2021)
" Here, diffusion MRI data were acquired in a GL261 glioma mouse model before and during treatment with Temozolomide."	3.96	Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. ( Agliardi, G; Alexander, DC; Atkinson, D; Brandner, S; Breen-Norris, JO; d'Esposito, A; Hipwell, B; Hyare, H; Ianus, A; Lythgoe, MF; Panagiotaki, E; Punwani, S; Ramasawmy, R; Rees, J; Roberts, TA; Siow, B; Taylor, V; Walker-Samuel, S, 2020)
"This retrospective analysis investigated outcomes in patients with anaplastic oligodendroglioma 1p19q codeleted compared two different protocols (radiotherapy plus temozolomide or PCV)."	3.88	Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( Castro-Martinez, E; Gonzalez-Aguilar, A; Guerrero-Juarez, V; Gutierrez-Aceves, A; Hernandez-Hernandez, A; Lopez-Martinez, M; Peiro-Osuna, RP; Reyes-Moreno, I; Santos-Zambrano, J, 2018)
"The current standard of care for glioblastoma (GBM) involves a combination of surgery, radiotherapy, and temozolomide chemotherapy, but this regimen fails to achieve long-term tumor control."	3.80	Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( Cairncross, JG; Luchman, HA; Lun, XQ; Nguyen, SA; Robbins, SM; Senger, DL; Stechishin, OD; Weiss, S, 2014)
" In addition, microsatellite instability, leading to the putative mechanism of temozolomide (TMZ) resistance, was frequently detected."	3.79	Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics. ( Amano, T; Fujioka, Y; Hata, N; Iwaki, T; Mizoguchi, M; Murata, H; Nakamizo, A; Sasaki, T; Suzuki, SO; Yoshimoto, K, 2013)
" We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)."	3.79	IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013)
"To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide."	3.73	Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. ( Franz, M; Grosu, AL; Gumprecht, H; Molls, M; Nieder, C; Piert, M; Schwaiger, M; Stärk, S; Thamm, R; Weber, WA, 2005)
"In this IRB-approved retrospective study, we analyzed the efficacy of temozolomide on World Health Organization Grade II and III oligodendrogliomas, as well as mixed oligoastrocytomas, to determine if a correlation exists between the tumors' 1p status and control of growth by this new oral agent."	3.72	Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. ( Barnett, G; Chahlavi, A; Elson, P; Kanner, A; Peereboom, D; Staugaitis, SM, 2003)
"We conducted a retrospective observational study that included patients with recurrent malignant glioma who where treated with temozolomide."	3.72	Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. ( Maltoni, S; Messori, A; Pelagotti, F; Trippoli, S; Vacca, F; Vaiani, M, 2003)
"The authors determined the tolerance, response rate, and duration of recurrent anaplastic oligodendroglioma in 30 patients to temozolomide given orally at 150 to 200 mg/m2 on days 1 through 5 in cycles of 28 days."	3.71	Temozolomide chemotherapy in recurrent oligodendroglioma. ( Brandes, AA; Carpentier, AF; Eskens, FA; Keime-Guibert, F; Kros, JM; Taphoorn, MJ; van den Bent, MJ, 2001)
"Temozolomide was given 150 mg/m(2) days 1-7 and 15-21, every 28 days for 8 cycles."	2.80	Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( Ahluwalia, MS; Brewer, C; Chamberlain, MC; Dahiya, S; Elson, P; Fisher, PG; Hashemi-Sadraei, N; Newton, HB; Pannullo, S; Peereboom, DM; Prayson, R; Schiff, D; Wood, L; Xie, H, 2015)
"The treatment of patients with anaplastic oligodendroglioma (AO) has been significantly impacted by the molecular detection of loss of sequences on chromosomes 1p and 19q."	2.74	Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma. ( Anderson, J; Avedissian, R; Croteau, D; Doyle, T; Gutierrez, J; Hasselbach, L; Margolis, J; Mikkelsen, T; Paleologos, N; Schultz, L, 2009)
"The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known."	2.71	Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. ( Gomori, JM; Levin, N; Siegal, T, 2004)
"Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity."	2.71	Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004)
"Temozolomide was in general well tolerated; the most frequent side-effects were hematological."	2.71	Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003)
"The tumor, a grade 3 anaplastic oligodendroglioma, was excised, and chemoradiotherapy was administered."	2.55	Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature. ( Abraham Koshy, A; Kumar A, A, 2017)
"Anaplastic oligodendrogliomas have long attracted interest because of their sensitivity to chemotherapy, in particular in the subset of 1p/19q co-deleted tumors."	2.53	Low-grade and anaplastic oligodendroglioma. ( Bromberg, JE; Buckner, J; Van Den Bent, MJ, 2016)
"Abstract: Anaplastic oligodendroglioma (AO) is a rare malignant tumor occurring in adults."	2.49	Treatment recommendations for anaplastic oligodendrogliomas that are codeleted. ( Anderson, MD; Gilbert, MR, 2013)
"A case of anaplastic oligodendroglioma with femoral metastasis is presented in a 37-year old male with a 2-year history of progressive headaches and dizziness associated with a 2-month history of epilepsy and right hemiparesis."	2.47	Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature. ( Liu, B; Qu, L; Tao, H; Wu, Y, 2011)
"The incidence of oligodendroglioma is increasing, most likely due to its improved recognition."	2.42	Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. ( Engelhard, HH; Mundt, A; Stelea, A, 2003)
"Temozolomide-based treatment was administered to 64 of 68 (94."	1.72	Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. ( Aichholzer, M; Berghoff, AS; Dieckmann, K; Furtner, J; Goldberger, S; Hatziioannou, T; Heller, G; Leibetseder, A; Mair, MJ; Pichler, J; Preusser, M; Puhr, R; Tomasich, E; von Oertzen, T; Weis, S; Widhalm, G; Wöhrer, A, 2022)
"Oligodendroglioma is defined by IDH mutation and 1p/19q codeletion."	1.56	Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. ( Kamataki, A; Nanjo, H; Ono, T; Reinhardt, A; Shimizu, H; Takahashi, M; von Deimling, A, 2020)
"Pathology was anaplastic oligodendroglioma (AOD) and anaplastic astrocytoma IDH-mutated (AAmut) in 32 and 21 patients respectively."	1.51	Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. ( Back, M; Bailey, D; Brazier, D; Guo, L; Hsiao, E; Jayamanne, D; Wheeler, H, 2019)
"Oligodendrogliomas are therapy-responsive tumors, which have better prognosis compared to their astrocytic counterparts."	1.48	Chemotherapy of Oligodendrogliomas. ( Drappatz, J; Lieberman, F, 2018)
"Spinal cord oligodendrogliomas are rare tumors, with a reported incidence varying between 0."	1.43	Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. ( Cachia, D; Cykowski, MD; Jalali, A; Langford, LA; Li, J; Penas-Prado, M; Shah, K; Strickland, BA; Weinberg, JS, 2016)
"Optic pathway oligodendrogliomas are a rare form of pediatric intracranial tumor."	1.40	Case of pediatric optic pathway oligodendroglioma presenting widespread invasion and dissemination in the cerebrospinal fluid. ( Asano, K; Ito, E; Katayama, K; Komori, T; Ohkuma, H; Sasaki, S; Sato, T; Terui, K, 2014)
"Extracranial metastasis of primary brain tumors is rarely observed."	1.38	Breast metastasis of anaplastic oligodendroglioma: a case report. ( Alacacioglu, A; Canpolat, S; Coskun, A; Karatas, A; Oztekin, O; Postaci, H; Sop, G; Unal, S; Yurt, A, 2012)
"Histology revealed an anaplastic oligodendroglioma."	1.37	Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide. ( Lou, X; Qiao, G; Wang, F, 2011)
"Gliomas account for more than 50% of all primary brain tumors."	1.36	Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. ( Bontempi, G; Bruyère, C; Decaestecker, C; Dubois, J; Haibe-Kains, B; Kiss, R; Lamoral-Theys, D; Le Calvé, B; Le Mercier, M; Lefranc, F; Rynkowski, MA, 2010)
"Malignant astrocytic brain tumors are among the most lethal cancers."	1.36	Non-stem cell origin for oligodendroglioma. ( Auvergne, R; Ayers-Ringler, J; Berger, MS; Bergers, G; Goldenberg, DD; Goldman, SA; Itsara, M; McKnight, TR; Nguyen, KN; Nishiyama, A; Persson, AI; Petritsch, C; Sim, FJ; Stallcup, WB; Swartling, FJ; Vandenberg, SR; Weiss, WA; Yakovenko, S, 2010)
"The diagnosis of an anaplastic oligodendroglioma (WHO grade 3) was made on pathological examination."	1.35	Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. ( Chaskis, C; Michotte, A; Neyns, B; Sadones, J; Veld, PI, 2009)
"At the time of the initial disease recurrence, 13 patients were readministered TMZ."	1.33	Salvage temozolomide for prior temozolomide responders. ( Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM, 2005)
"Secondary anaplastic oligodendroglioma patients were younger than patients with de novo anaplastic oligodendrogliomas."	1.32	Long-term outcome of oligodendrogliomas. ( Bourg, V; Chanalet, S; Chatel, M; Fontaine, D; Frenay, M; Lebrun, C; Lonjon, M; Michiels, JF; Paquis, P; Ramaioli, A; Vandenbos, F, 2004)

Research

Studies (103)

Authors

Clinical Trials (11)

Trial Overview

Trial Outcomes

Number of Participants Evaluated for Toxicities

Progession Free Survival

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.94)	18.2507
2000's	37 (35.92)	29.6817
2010's	48 (46.60)	24.3611
2020's	16 (15.53)	2.80

Authors	Studies
Barresi, V	1
Mafficini, A	1
Calicchia, M	1
Piredda, ML	1
Musumeci, A	1
Ghimenton, C	3
Scarpa, A	1
Dono, A	1
Alfaro-Munoz, K	1
Yan, Y	1
Lopez-Garcia, CA	1
Soomro, Z	1
Williford, G	1
Takayasu, T	1
Robell, L	1
Majd, NK	1
de Groot, J	1
Esquenazi, Y	1
Kamiya-Matsuoka, C	1
Ballester, LY	1
Tom, MC	1
Milano, MT	1
Chao, ST	1
Soltys, SG	1
Knisely, JPS	1
Sahgal, A	1
Nagpal, S	1
Lo, SS	1
Jabbari, S	1
Wang, TJC	1
Ahluwalia, MS	2
Simonson, M	1
Palmer, JD	1
Gephart, MH	1
Halasz, LM	1
Garg, AK	1
Chiang, VLS	1
Chang, EL	1
Garnier, L	1
Vidal, C	1
Chinot, O	5
Cohen-Jonathan Moyal, E	1
Djelad, A	1
Bronnimann, C	1
Bekaert, L	1
Taillandier, L	4
Frenel, JS	1
Langlois, O	1
Colin, P	1
Menei, P	1
Dhermain, F	2
Carpentier, C	2
Gerazime, A	1
Curtit, E	1
Figarella-Branger, D	2
Dehais, C	2
Ducray, F	2
Jo, J	1
Schiff, D	5
Mair, MJ	1
Leibetseder, A	1
Heller, G	1
Puhr, R	1
Tomasich, E	1
Goldberger, S	1
Hatziioannou, T	1
Wöhrer, A	1
Widhalm, G	1
Dieckmann, K	1
Aichholzer, M	1
Weis, S	1
von Oertzen, T	1
Furtner, J	1
Pichler, J	1
Preusser, M	1
Berghoff, AS	1
Ehret, F	1
Hansch, A	1
Meinhardt, J	1
Hain, EG	1
Misch, M	1
Onken, J	1
Roohani, S	1
Koch, A	1
Schweizer, L	1
Radke, J	1
Kaul, D	1
Roberts, TA	1
Hyare, H	1
Agliardi, G	1
Hipwell, B	1
d'Esposito, A	1
Ianus, A	1
Breen-Norris, JO	1
Ramasawmy, R	1
Taylor, V	1
Atkinson, D	1
Punwani, S	1
Lythgoe, MF	1
Siow, B	1
Brandner, S	1
Rees, J	1
Panagiotaki, E	1
Alexander, DC	1
Walker-Samuel, S	1
Jaeckle, KA	1
Ballman, KV	1
van den Bent, M	2
Giannini, C	3
Galanis, E	1
Brown, PD	1
Jenkins, RB	2
Cairncross, JG	6
Wick, W	1
Weller, M	3
Aldape, KD	3
Dixon, JG	1
Anderson, SK	1
Cerhan, JH	1
Wefel, JS	1
Klein, M	1
Grossman, SA	1
Raizer, JJ	1
Nordstrom, DG	1
Flynn, PJ	1
Vogelbaum, MA	3
Ono, T	1
Reinhardt, A	1
Takahashi, M	1
Nanjo, H	1
Kamataki, A	1
von Deimling, A	2
Shimizu, H	1
Rudà, R	2
Touat, M	1
Soffietti, R	3
Lassman, AB	5
Cloughesy, TF	3
Weller, J	1
Katzendobler, S	1
Karschnia, P	1
Lietke, S	1
Egensperger, R	1
Thon, N	1
Suchorska, B	1
Tonn, JC	1
Guo, Z	1
Li, D	1
Xie, Y	1
Qian, J	1
Zhao, B	1
Anand, S	1
Chatterjee, A	1
Gupta, T	2
Panda, P	1
Moiyadi, A	2
Epari, S	2
Patil, V	1
Krishnatry, R	1
Goda, JS	2
Jalali, R	2
Carroll, KT	1
Hirshman, B	1
Ali, MA	1
Alattar, AA	1
Brandel, MG	1
Lochte, B	1
Lanman, T	1
Carter, B	1
Chen, CC	1
Tokuda, Y	1
Tamura, R	1
Ohara, K	1
Yoshida, K	1
Sasaki, H	1
Thomas, AA	1
Abrey, LE	4
Terziev, R	1
Raizer, J	1
Martinez, NL	1
Forsyth, P	1
Paleologos, N	2
Matasar, M	1
Sauter, CS	1
Moskowitz, C	1
Nimer, SD	1
DeAngelis, LM	3
Kaley, T	1
Grimm, S	1
Louis, DN	4
Panageas, KS	3
Briggs, S	1
Faivre, G	1
Mohile, NA	1
Mehta, J	1
Jonsson, P	1
Chakravarty, D	1
Gao, J	1
Schultz, N	1
Brennan, CW	1
Huse, JT	1
Omuro, A	2
Sorge, C	1
Li, R	1
Singh, S	1
Reddy, AT	1
Solomon, DA	1
Perry, A	1
Friedman, GK	1
Kumar A, A	1
Abraham Koshy, A	1
Drappatz, J	1
Lieberman, F	1
Holdhoff, M	1
Gonzalez-Aguilar, A	1
Reyes-Moreno, I	1
Peiro-Osuna, RP	1
Hernandez-Hernandez, A	1
Gutierrez-Aceves, A	1
Santos-Zambrano, J	1
Guerrero-Juarez, V	1
Lopez-Martinez, M	1
Castro-Martinez, E	1
Back, M	2
Jayamanne, D	2
Brazier, D	2
Bailey, D	2
Hsiao, E	2
Guo, L	1
Wheeler, H	2
Franceschi, E	3
Tosoni, A	3
De Biase, D	1
Lamberti, G	1
Danieli, D	1
Pizzolitto, S	1
Zunarelli, E	1
Visani, M	1
Di Oto, E	1
Mura, A	1
Minichillo, S	1
Scafati, C	1
Asioli, S	1
Paccapelo, A	1
Bartolini, S	1
Brandes, AA	6
Newey, A	1
Schembri, G	1
Khasraw, M	1
Wong, M	1
Kastelan, M	1
Brown, C	1
Mizoguchi, M	1
Hata, N	1
Suzuki, SO	1
Fujioka, Y	1
Murata, H	1
Amano, T	1
Nakamizo, A	1
Yoshimoto, K	1
Iwaki, T	1
Sasaki, T	1
Anderson, MD	1
Gilbert, MR	1
Katayama, K	1
Asano, K	1
Ohkuma, H	1
Terui, K	1
Sasaki, S	1
Sato, T	1
Ito, E	1
Komori, T	1
Sha, SJ	1
Wu, HP	1
Lu, K	1
Chen, HJ	1
Huang, PH	1
Huang, SH	1
Hsu, CT	1
Smirnova, ZS	1
Ermakova, KV	1
Kubasova, IY	1
Borisova, LM	1
Kiselyova, MP	1
Oborotova, NA	1
Meerovich, GA	1
Luk'yanets, EA	1
Nguyen, SA	1
Stechishin, OD	1
Luchman, HA	1
Lun, XQ	1
Senger, DL	1
Robbins, SM	1
Weiss, S	1
Xie, H	1
Dahiya, S	1
Hashemi-Sadraei, N	1
Fisher, PG	1
Chamberlain, MC	4
Pannullo, S	1
Newton, HB	1
Brewer, C	1
Wood, L	1
Prayson, R	1
Elson, P	2
Peereboom, DM	2
Levin, VA	1
Rinne, ML	1
Wen, PY	3
Lewis, S	1
Agarwal, A	1
Churi, S	1
Padmavati, A	1
Shetty, P	1
Hu, C	1
Macdonald, DR	1
Suh, JH	2
Laack, NN	1
Brachman, DG	1
Shrieve, DC	1
Souhami, L	1
Mehta, MP	2
Strickland, BA	1
Cachia, D	1
Jalali, A	1
Cykowski, MD	1
Penas-Prado, M	1
Langford, LA	1
Li, J	1
Shah, K	1
Weinberg, JS	1
Van Den Bent, MJ	8
Bromberg, JE	1
Buckner, J	1
Hernandez-Lain, A	1
Hilario, A	1
Sepulveda, JM	1
Cantero, D	1
Ramos, A	1
Perez-Nuñez, A	1
Chi, AS	1
Cahill, DP	1
Larvie, M	1
Liu, R	1
Solheim, K	1
Polley, MY	1
Lamborn, KR	1
Page, M	1
Fedoroff, A	1
Rabbitt, J	1
Butowski, N	1
Prados, M	2
Chang, SM	1
Berkey, B	1
Peereboom, D	2
Macdonald, D	1
Jenkins, R	1
Herman, J	1
Brown, P	1
Blumenthal, DT	1
Biggs, C	1
Schultz, C	1
Mehta, M	1
Mikkelsen, T	1
Doyle, T	1
Anderson, J	1
Margolis, J	1
Gutierrez, J	1
Croteau, D	1
Hasselbach, L	1
Avedissian, R	1
Schultz, L	1
Oshiro, S	1
Tsugu, H	1
Komatsu, F	1
Ohmura, T	1
Ohta, M	1
Sakamoto, S	1
Fukushima, T	1
Inoue, T	1
Michotte, A	1
Chaskis, C	1
Sadones, J	1
Veld, PI	1
Neyns, B	1
Mandonnet, E	1
Pallud, J	1
Fontaine, D	2
Bauchet, L	1
Peruzzi, P	1
Guyotat, J	1
Bernier, V	1
Baron, MH	1
Duffau, H	3
Capelle, L	2
Passarin, MG	1
Moretto, G	1
Musso, AM	1
Ottaviani, S	1
Masotto, B	1
Iuzzolino, P	2
Buffone, E	1
Vattemi, E	1
Pedersini, R	1
Guillaume, DJ	1
Doolittle, ND	1
Gahramanov, S	1
Hedrick, NA	1
Delashaw, JB	1
Neuwelt, EA	1
Lamoral-Theys, D	1
Le Mercier, M	1
Le Calvé, B	1
Rynkowski, MA	1
Bruyère, C	1
Decaestecker, C	1
Haibe-Kains, B	1
Bontempi, G	1
Dubois, J	1
Lefranc, F	1
Kiss, R	1
Cho, KH	1
Kim, JY	1
Lee, SH	1
Yoo, H	1
Shin, SH	1
Moon, SH	1
Kim, TH	1
Shin, KH	1
Yoon, M	1
Lee, DH	1
Pyo, HR	1
Gan, HK	1
Rosenthal, MA	1
Dowling, A	1
Kalnins, R	1
Algar, E	1
Wong, N	1
Benson, A	1
Woods, AM	1
Cher, L	1
del Rio, MS	1
Psimaras, D	1
Idbaih, A	1
Kaloshi, G	1
Mokhtari, K	4
Taillibert, S	3
Laigle-Donadey, F	2
Sanson, M	5
Delattre, JY	4
Hoang-Xuan, K	3
Persson, AI	1
Petritsch, C	1
Swartling, FJ	1
Itsara, M	1
Sim, FJ	1
Auvergne, R	1
Goldenberg, DD	1
Vandenberg, SR	1
Nguyen, KN	1
Yakovenko, S	1
Ayers-Ringler, J	1
Nishiyama, A	1
Stallcup, WB	1
Berger, MS	1
Bergers, G	1
McKnight, TR	1
Goldman, SA	1
Weiss, WA	1
Wang, F	1
Qiao, G	1
Lou, X	1
Iwamoto, FM	2
Rivera, AL	2
Eichler, AF	2
Paleologos, NA	2
Fisher, BJ	2
Ashby, LS	2
Roldán, GB	1
Ligon, KL	2
Robins, HI	2
Rocque, BG	2
Mason, WP	3
Weaver, SA	2
Green, RM	2
Kamar, FG	2
Jhanwar, SC	2
Rosenblum, MK	2
Wu, Y	1
Liu, B	1
Qu, L	1
Tao, H	1
Chadarévian, JP	1
Legido, A	1
Halligan, GE	1
Faerber, EN	1
Piatt, JH	1
Morrissette, JD	1
Ara, J	1
Grant, ML	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma[NCT00588523]	Phase 2	60 participants (Actual)	Interventional	2002-09-30	Completed
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma[NCT00887146]	Phase 3	360 participants (Anticipated)	Interventional	2009-09-30	Recruiting
A Phase II Trial Of Pre-Irradiation And Concurrent Temozolomide In Patients With Newly Diagnosed Anaplastic Oligodendrogliomas And Mixed Anaplastic Oligoastrocytomas[NCT00033280]	Phase 2	42 participants (Actual)	Interventional	2002-07-31	Completed
A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793]	Phase 2	11 participants (Actual)	Interventional	2010-10-14	Terminated (stopped due to The clinical trial was terminated due to poor enrollment)
The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235]	Phase 2	23 participants (Actual)	Interventional	2013-05-31	Completed
Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304]	Phase 2	29 participants (Anticipated)	Interventional	1998-04-30	Completed
First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial[NCT00003731]	Phase 2	39 participants (Actual)	Interventional	1998-12-31	Completed
A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428]	Phase 2	54 participants (Actual)	Interventional	2014-06-30	Active, not recruiting
Amino-acid PET Versus MRI Guided Re-irradiation in Patients With Recurrent Glioblastoma Multiforme - a Randomised Phase II Trial[NCT01252459]	Phase 2	200 participants (Anticipated)	Interventional	2011-07-31	Not yet recruiting
Role of Repeat Resection in Recurrent Glioblastoma (4rGBM) Trial: a Randomized Care Trial for Patients With Recurrent GBM[NCT04838782]		250 participants (Anticipated)	Interventional	2021-08-26	Recruiting
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors[NCT00994071]	Phase 1	9 participants (Actual)	Interventional	2009-09-22	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
Participants With Newly Diagnosed Anaplastic Oligodendroglioma	60

To determine the duration of disease control of newly diagnosed pure and mixed anaplastic oligodendrogliomas treated with dose-intensive chemotherapy requiring hematopoietic stem cell support. (NCT00588523)
Timeframe: 2 years

Safest Dose of Temozolomide for the DRBEAT Regimen

Intervention	% of participants without progression (Number)
Participants With Newly Diagnosed Anaplastic Oligodendroglioma	85.7

Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year

One-year Progression-free Survival and Overall Survival

Intervention	dose in mg/m^2 (Number)
DRBEAT Regimen	773.25

"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years

Intervention	Days (Median)
	Progression Free Survival	Overall Survival
DRBEAT Regimen	132	564

Article	Year
Executive summary of American Radium Society's appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022, Volume: 170 Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Oligodendroglioma; Radium; Temozolomide	2022
Current Considerations in the Treatment of Grade 3 Gliomas. Current treatment options in oncology, 2022, Volume: 23, Issue:9 Topics: Astrocytoma; Brain Neoplasms; Glioma; Humans; Isocitrate Dehydrogenase; Lymphoma, Follicular; Mutati	2022
Is chemotherapy alone an option as initial treatment for low-grade oligodendrogliomas? Current opinion in neurology, 2020, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Humans; Lomustine; Oligodendroglioma; Temozolomide; Treatmen	2020
Secondary cerebellopontine angle oligodendroglioma after cranial irradiation: a case report and literature review. The International journal of neuroscience, 2023, Volume: 133, Issue:4 Topics: Adult; Astrocytoma; Cerebellopontine Angle; Cranial Irradiation; Humans; Magnetic Resonance Imaging;	2023
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. Pediatric blood & cancer, 2017, Volume: 64, Issue:12 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Dacarbazine; Humans; Isocitrate Dehydroge	2017
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature. World neurosurgery, 2017, Volume: 108 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Ca	2017
Treatment recommendations for anaplastic oligodendrogliomas that are codeleted. Oncology (Williston Park, N.Y.), 2013, Volume: 27, Issue:4 Topics: Brain Neoplasms; Dacarbazine; Humans; Isocitrate Dehydrogenase; Mutation; Oligodendroglioma; Temozol	2013
Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen? CNS oncology, 2015, Volume: 4, Issue:5 Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Humans; Lomustine; Ol	2015
Low-grade and anaplastic oligodendroglioma. Handbook of clinical neurology, 2016, Volume: 134 Topics: Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; DNA Modification Methyl	2016
Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. International journal of radiation oncology, biology, physics, 2010, Oct-01, Volume: 78, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H	2010
Extracranial skeletal metastasis in anaplastic oligodendroglioma: case report and review of the literature. The Journal of international medical research, 2011, Volume: 39, Issue:3 Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dacarbazine; Femur; Humans; Magnetic Reson	2011
Cerebellar gliomatosis in a toddler: case report of a challenging condition and review of the literature. Journal of child neurology, 2012, Volume: 27, Issue:4 Topics: Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Cerebellum; Child, Preschool; Dacarbazine;	2012
Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncology, 2003, Volume: 5, Issue:2 Topics: Animals; Astrocytoma; Clinical Trials as Topic; Dacarbazine; Humans; Oligodendroglioma; Temozolomide	2003
Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surgical neurology, 2003, Volume: 60, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine	2003
Bony metastases of anaplastic oligodendroglioma respond to temozolomide. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2004, Volume: 31, Issue:1 Topics: Adult; Bone Neoplasms; Dacarbazine; Humans; Male; Oligodendroglioma; Retrospective Studies; Temozolo	2004
Neuro-oncology: the growing role of chemotherapy in glioma. The Lancet. Neurology, 2005, Volume: 4, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; D	2005
Response of low-grade oligodendroglial tumors to temozolomide. Journal of neuro-oncology, 2004, Volume: 70, Issue:3 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Controlled Clinical	2004
Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro-oncology, 2006, Volume: 8, Issue:3 Topics: Aged; Breast Neoplasms; Dacarbazine; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndr	2006
Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Critical reviews in oncology/hematology, 2006, Volume: 60, Issue:2 Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carcinoma; Chemotherapy, Adjuvant;	2006
[Pattern of care of high-grade gliomas]. La Revue du praticien, 2006, Oct-31, Volume: 56, Issue:16 Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin	2006
Molecular targeted therapies and chemotherapy in malignant gliomas. Current opinion in oncology, 2007, Volume: 19, Issue:6 Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Dacarbazine; Disease-Free Survival	2007
[Recent advances in chemotherapy for malignant gliomas]. No shinkei geka. Neurological surgery, 2008, Volume: 36, Issue:2 Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dacarbazine; DNA Repair; Glioma; Humans; Meta-A	2008
New chemotherapy options for the treatment of malignant gliomas. Current opinion in oncology, 1999, Volume: 11, Issue:3 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Camptothecin; Clinical Trials as Topic; Dacarbazine;	1999
Chemotherapy for the treatment of oligodendroglial tumors. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 13 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Nervous S	2001

Article	Year
Recurrent oligodendroglioma with changed 1p/19q status. Neuropathology : official journal of the Japanese Society of Neuropathology, 2022, Volume: 42, Issue:2 Topics: Brain Neoplasms; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosome	2022
Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery, 2022, 05-01, Volume: 90, Issue:5 Topics: Adult; Brain Neoplasms; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Male; Oligodendrogli	2022
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study. The oncologist, 2022, 05-06, Volume: 27, Issue:5 Topics: Brain Neoplasms; Chromosome Aberrations; Humans; Oligodendroglioma; Retrospective Studies; Survivors	2022
Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-14, Volume: 28, Issue:20 Topics: Adult; Brain Neoplasms; DNA Methylation; Humans; Isocitrate Dehydrogenase; Lomustine; Methyltransfer	2022
Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH-mutant and 1p/19q-codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report. Neuropathology and applied neurobiology, 2023, Volume: 49, Issue:1 Topics: Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Glioma; Humans; Isocitrate	2023
Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. Scientific reports, 2020, 06-08, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Diffusio	2020
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. Acta neurochirurgica, 2020, Volume: 162, Issue:12 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Female; Humans; Isocitrate Dehydrogenase;	2020
Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile? Neuro-oncology, 2021, 03-25, Volume: 23, Issue:3 Topics: Brain Neoplasms; Dacarbazine; Humans; Oligodendroglioma; Temozolomide	2021
PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. Journal of neuro-oncology, 2021, Volume: 153, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Humans; Lomustine; Neoplasm Staging	2021
Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy. World neurosurgery, 2021, Volume: 154 Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Chemoradi	2021
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis. World neurosurgery, 2017, Volume: 103 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain N	2017
A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery. Brain tumor pathology, 2017, Volume: 34, Issue:2 Topics: Adult; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Craniotomy; Dacarbazine; Humans; Int	2017
Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role? Neuro-oncology, 2017, 10-01, Volume: 19, Issue:10 Topics: Adult; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 19; Humans; Oligodendroglioma; Stem Cell	2017
Chemotherapy of Oligodendrogliomas. Progress in neurological surgery, 2018, Volume: 31 Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine	2018
Role of Molecular Pathology in the Treatment of Anaplastic Gliomas and Glioblastomas. Journal of the National Comprehensive Cancer Network : JNCCN, 2018, Volume: 16, Issue:5S Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain; Brain Neoplasms; Chemoradiotherapy, Adj	2018
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. Revista de neurologia, 2018, Oct-16, Volume: 67, Issue:8 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai	2018
Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic glioma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2019, Volume: 59 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Female; Humans;	2019
Postsurgical Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone Still an Option? The oncologist, 2019, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas	2019
Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:1 Topics: Adult; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; DNA Mutational Analysis; Female; Fol	2020
Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics. Neuropathology : official journal of the Japanese Society of Neuropathology, 2013, Volume: 33, Issue:6 Topics: Brain Neoplasms; Chemoradiotherapy; Child; Dacarbazine; Fatal Outcome; Glioblastoma; Humans; Male; M	2013
Case of pediatric optic pathway oligodendroglioma presenting widespread invasion and dissemination in the cerebrospinal fluid. Brain tumor pathology, 2014, Volume: 31, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy, Adjuvant; Child; Dac	2014
Extraneural metastases of anaplastic oligodendroglioma. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2014, Volume: 122, Issue:7 Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Neoplasms; Dacarbazine; Humans; Lymphatic M	2014
Experimental study of combined therapy for malignant glioma. Bulletin of experimental biology and medicine, 2014, Volume: 156, Issue:4 Topics: Animals; Animals, Outbred Strains; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;	2014
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Sep-15, Volume: 20, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Brain	2014
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:4 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;	2015
Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Williston Park, N.Y.), 2015, Volume: 29, Issue:4 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj	2015
Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma? Clinical neurology and neurosurgery, 2015, Volume: 135 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Ne	2015
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. Neurosurgery, 2016, Volume: 78, Issue:3 Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Humans; Magnetic Resonance	2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of High-Grade Glioma. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Beva	2015
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma. Neurology, 2016, 07-05, Volume: 87, Issue:1 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin	2016
Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. The New England journal of medicine, 2016, 12-15, Volume: 375, Issue:24 Topics: Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dia	2016
Quality of life in low-grade glioma patients receiving temozolomide. Neuro-oncology, 2009, Volume: 11, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; H	2009
Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer research, 2009, Volume: 29, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemother	2009
Primary leptomeningeal anaplastic oligodendroglioma with a 1p36-19q13 deletion: report of a unique case successfully treated with Temozolomide. Journal of the neurological sciences, 2009, Dec-15, Volume: 287, Issue:1-2 Topics: Antineoplastic Agents, Alkylating; Arachnoid; Brain; Chromosomes, Human, Pair 1; Chromosomes, Human,	2009
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection. Neurosurgical review, 2010, Volume: 33, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi	2010
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. Journal of neuro-oncology, 2010, Volume: 97, Issue:3 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytar	2010
Long-term temozolomide treatment induces marked amino metabolism modifications and an increase in TMZ sensitivity in Hs683 oligodendroglioma cells. Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:1 Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Brain Neoplas	2010
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. Journal of neuro-oncology, 2011, Volume: 101, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; DNA Methyl	2011
Non-stem cell origin for oligodendroglioma. Cancer cell, 2010, Dec-14, Volume: 18, Issue:6 Topics: Animals; Antigens; Benzamides; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Dacarbazine;	2010
Spinal cord anaplastic oligodendroglioma with 1p deletion: report of a relapsing case treated with temozolomide. Journal of neuro-oncology, 2011, Volume: 104, Issue:1 Topics: Adolescent; Antineoplastic Agents, Alkylating; Chromosome Deletion; Chromosomes, Human, Pair 1; Daca	2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology, 2011, Volume: 13, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr	2011
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta neuropathologica, 2012, Volume: 123, Issue:6 Topics: Adolescent; Adult; Aged; Brain Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Da	2012
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro-oncology, 2012, Volume: 14, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem	2012
Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro-oncology, 2012, Volume: 14, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chem	2012
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. Brain tumor pathology, 2013, Volume: 30, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Ther	2013
Decision making and management of gliomas: practical considerations. Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10 Topics: Aged; Astrocytoma; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; DNA Modification Methylases; DNA	2012
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors. Pathology, research and practice, 2012, Dec-15, Volume: 208, Issue:12 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human,	2012
Breast metastasis of anaplastic oligodendroglioma: a case report. Tumori, 2012, Volume: 98, Issue:6 Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiothera	2012
Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology, 2003, Mar-11, Volume: 60, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat	2003
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. Journal of neuro-oncology, 2003, Volume: 61, Issue:3 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Dacarba	2003
Survival of patients with recurrent malignant glioma treated with temozolomide: a retrospective observational study. Drugs in R&D, 2003, Volume: 4, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Central Nervous Syst	2003
Long-term outcome of oligodendrogliomas. Neurology, 2004, May-25, Volume: 62, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Ci	2004
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer research, 2004, Jul-01, Volume: 64, Issue:13 Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarba	2004
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-01, Volume: 22, Issue:15 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chromosome Deletion; C	2004
Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. International journal of radiation oncology, biology, physics, 2005, Oct-01, Volume: 63, Issue:2 Topics: Adult; Aged; alpha-Methyltyrosine; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocyt	2005
Salvage temozolomide for prior temozolomide responders. Cancer, 2005, Dec-01, Volume: 104, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G	2005
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer, 2006, Apr-15, Volume: 106, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pai	2006
Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma. Epilepsia, 2006, Volume: 47, Issue:7 Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comorbidity; Dacarbazine	2006
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human,	2006
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human,	2006
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human,	2006
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:15 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pair 1; Chromosomes, Human,	2006
Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide. Anti-cancer drugs, 1999, Volume: 10, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Dose-Response R	1999
Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology, 2001, Jul-24, Volume: 57, Issue:2 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Humans; Middle Aged; Neoplasm Recurrence	2001

temozolomide and Anaplastic Oligodendroglioma